arav-8k_20210506.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2021

 

Aravive, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-36361

 

26-4106690

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

River Oaks Tower

3730 Kirby Drive, Suite 1200

Houston, Texas 77098

(Address of principal executive offices)

 

(936) 355-1910

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common stock, par value $0.0001 per share

 

ARAV

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 


 

Item 2.02. Results of Operation and Financial Condition

On May 6, 2021, Aravive, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.  The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 7.01.   Regulation FD Disclosure.

The Company will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the investor presentation, which is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01, and in the investor presentation furnished as Exhibit 99.2 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and  shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished to this Current Report on Form 8-K:

 

Exhibit

  

Description

99.1

  

Press Release dated May 6, 2021

99.2

 

Aravive, Inc. Investor Presentation dated May 2021

 

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 6, 2021

ARAVIVE, INC.

(Registrant)

 

 

 

By:

 

/s/ Gail McIntyre

 

 

 

Name: Gail McIntyre

Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

arav-ex991_181.htm

Exhibit 99.1

 

 

Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate
AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

 

 

Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer

 

First patient dosed in registrational Phase 3 trial of AVB-500 in platinum resistant ovarian cancer; on track to conduct interim analysis in first quarter 2022

 

First patient dosed in Phase 1b/2 trial of AVB-500 in clear cell renal cell carcinoma; on track to report topline data in second half 2021

 

HOUSTON, May 6, 2021 – Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced recent corporate updates and financial results for the first quarter ended March 31, 2021.

 

“We are rapidly advancing development of AVB-500, while at the same time, expanding into additional oncology indications. We began dosing patients in our registrational Phase 3 trial in platinum resistant ovarian cancer and our Phase 1b/2 trial in clear cell renal cell carcinoma,” said Gail McIntyre, Ph.D., Chief Executive Officer of Aravive. “We plan to expand the development of AVB-500 as a first-line treatment of pancreatic cancer, another area of oncology where there is a high, unmet medical need. We look forward to initiating the Phase 1b portion of this clinical trial in the second half of 2021. We are optimistic about the broad potential of AVB-500 in the treatment of multiple cancers and multiple indications, as we advance and expand our pipeline.”

 

Recent Corporate Highlights

Aravive to Expand Development of AVB-500 with Plans to Investigate AVB-500 in a Clinical Trial as a First-Line Treatment for Pancreatic Cancer: Aravive plans to expand development of AVB-500 in a Phase 1b/2 trial as a first-line treatment for pancreatic cancer. The expected design of the trial will evaluate AVB-500 in combination with gemcitabine and nab-paclitaxel (Abraxane®) in patients with advanced metastatic pancreatic cancer eligible to receive gemcitabine and nab-paclitaxel (Abraxane®) combination therapy. The Phase 1b portion of the clinical trial will assess safety, tolerability, and clinical activity of AVB-500 in combination with gemcitabine and nab-paclitaxel (Abraxane®). The randomized, controlled Phase 2 portion of the clinical trial will evaluate AVB-500 in combination with gemcitabine and nab-paclitaxel (Abraxane®) versus gemcitabine and nab-paclitaxel (Abraxane®) alone. The Company expects to initiate the Phase 1b portion of the clinical trial in the second half of 2021.

 

It is estimated that there will be approximately 60,400 new cases of pancreatic cancer and 48,200 deaths from the disease in the U.S. in 2021. Pancreatic cancer typically has a poor prognosis and the five-year survival rate is approximately 11%. There is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the second leading cause of cancer death in the U.S. by 2030.

AVB-500 in Platinum Resistant Ovarian Cancer (PROC): In April 2021, Aravive dosed the first patient in its registrational Phase 3 trial of AVB-500 in PROC and simplified the trial’s statistical analysis plan. The global, randomized, double-blind, placebo-controlled adaptive trial is designed to evaluate efficacy and safety of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel versus paclitaxel alone. The primary endpoint is progression-free survival. The trial is expected to enroll

 


 

approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy at approximately 165 sites in the U.S. and Europe. A prospectively defined interim analysis will determine whether randomization will continue with all patients, regardless of prior bevacizumab treatment, or only with patients medically ineligible to receive bevacizumab or who chose not to receive bevacizumab. The Company is on track to conduct the interim analysis in the first quarter of 2022.

AVB-500 in Clear Cell Renal Cell Carcinoma (ccRCC): In March 2021, Aravive dosed the first patient in its Phase 1b/2 trial of AVB-500 in ccRCC. The Phase 1b portion of the clinical trial is expected to enroll up to 18 patients in three dosing arms (15 mg/kg, 20 mg/kg and 25 mg/kg) to evaluate tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with cabozantinib. The controlled, randomized, open-label Phase 2 portion of the clinical trial will enroll up to 45 patients and investigate the recommended AVB-500 dose identified during the Phase 1b portion of the clinical trial in combination with cabozantinib versus cabozantinib alone. The primary endpoint is progression-free survival. The Company is on track to report topline data from the Phase 1b portion of the clinical trial in the second half of 2021.

Achieved First Clinical Milestone with 3D Medicines and Expected to Receive $6.0 Million Development Milestone Payment: In April 2021, Aravive dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer, and based upon this event, the Company successfully completed its first clinical milestone with 3D Medicines Inc. (3D Medicines). Aravive’s collaboration and license agreement with 3D Medicines is for the development and commercialization of AVB-500 for oncology indications in Greater China. Under the terms of the agreement, Aravive is eligible to receive up to an aggregate of $207 million in development and commercial milestone payments and royalties.

 

First Quarter 2021 Financial Results

Revenue for the three months ended March 31, 2021 was $0.3 million, compared to $0 for the same period in 2020. Revenue for the first quarter of 2021 was derived solely from the Company’s collaboration and license agreement with 3D Medicines.

 

Total operating expenses for the three months ended March 31, 2021 were $8.3 million, compared to $10.3 million for the same period in 2020.

 

Total operating expenses for the three months ended March 31, 2021 included non-cash stock-based compensation expense of $0.5 million, compared to $0.7 million for the same period in 2020. In addition, during the three months ended March 31, 2020, there were non-recurring non-cash charges for impairment of the Company’s right-of-use asset and leasehold improvements of $2.9 million.

 

For the three months ended March 31, 2021, Aravive reported a net loss of $8.0 million, or $0.44 per share, compared to a net loss of $10.8 million, or $0.72 per share, for the same period in 2020.

 

Cash Position

As of March 31, 2021, cash and cash equivalents were $78.7 million, compared to $60.5 million as of December 31, 2020. The Company expects that its current cash and cash equivalents will be sufficient to fund its operating plans into the second half of 2022.

  

About Pancreatic Cancer

Pancreatic cancer is the seventh leading cause of cancer death worldwide. There were approximately 495,800 new cases of pancreatic cancer and 466,000 deaths from the disease worldwide in 2020. It is estimated that there will be approximately 60,400 new cases of pancreatic cancer and 48,200 deaths from

 


 

the disease in the U.S. in 2021. Pancreatic cancer typically has a poor prognosis and the five-year survival rate is approximately 11%. There is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by 2025 and the second leading cause of cancer death in the U.S. by 2030.

 

About AVB-500

AVB-500 is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian cancer. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. AVB-500 is currently being evaluated in clinical trials and has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals.

About the Phase 3 PROC Trial

The global, randomized, double-blind, placebo-controlled adaptive trial (GOG-3059/ENGOT OV-66) is designed to evaluate efficacy and safety of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel. The trial is expected to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy at approximately 165 sites in the U.S. and Europe. The primary endpoint for the trial is progression free survival and the secondary endpoint is overall survival. Exploratory endpoints include objective response rate, duration of response, quality of life, clinical benefit rate, pharmacokinetic and pharmacodynamic profile, and sAXL/GAS6 ratio. A prospectively defined interim analysis will determine whether randomization will continue with all patients, regardless of prior bevacizumab treatment, or only with patients medically ineligible to receive bevacizumab or who chose not to receive bevacizumab. This trial is being conducted in partnership with The GOG Foundation, Inc. (GOG-F), through the GOG Partners program in the USA and in partnership with the European Network for Gynaecological Oncological Trial (ENGOT) groups in Europe. The Phase 3 trial is listed on clinicaltrials.gov NCT04729608.

 

About Aravive

Aravive, Inc. is a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is a first-in-class ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. AVB-500 has the potential to be combined with multiple anti-cancer therapies across several tumor types, due to its novel mechanism of action and favorable safety profile. AVB-500 has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The Company is currently evaluating AVB-500 in a registrational Phase 3 trial in platinum resistant ovarian cancer and a Phase 1b/2 trial in clear cell renal cell carcinoma. Aravive plans to initiate a Phase 1b/2 trial evaluating AVB-500 in first-line treatment of pancreatic cancer in the second half of 2021. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

 

 


 

 

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions and includes statements regarding plans to expand development of AVB-500 in a Phase 1b/2 trial as a first-line treatment for pancreatic cancer, initiating the Phase 1b portion of the trial in the second half of 2021, the expected design of the Phase 1b/2 trial as a first-line treatment for pancreatic cancer evaluating AVB-500 in combination with gemcitabine and nab-paclitaxel (Abraxane®) in patients with advanced metastatic pancreatic cancer eligible to receive gemcitabine and nab-paclitaxel (Abraxane®) combination therapy, the broad potential of AVB-500 in the treatment of multiple cancers and multiple indications, enrolling 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy at approximately 165 sites in the U.S. and Europe in the PROC Phase 3 trial, being on track to conduct an interim analysis in the PROC Phase 3 trial in the first quarter of 2022, the enrollment of up to 18 patients in three dosing arms (15 mg/kg, 20 mg/kg and 25 mg/kg) to evaluate tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with cabozantinib in the Phase 1b clear cell renal cell carcinoma clinical trial, being on track to report topline data from the Phase 1b portion of the clear cell renal cell carcinoma clinical trial in the second half of 2021 and receipt of a $6 million development milestone payment from 3D Medicines. Forward-looking statements are based on current beliefs and assumptions, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement as a result of various factors, including, but not limited to, risks and uncertainties related to: the Company’s ability to recruit for and enroll the expected number of patients into the Phase 3 trial of AVB-500 in PROC, its Phase 1b clear cell renal cell carcinoma clinical trial and its other trials as planned and its ability to report data as planned, the impact of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising, the Company's ability to expand development into pancreatic cancer as a first-line treatment and other additional oncology indications, the Company's dependence upon AVB-500, AVB-500's ability to have favorable results in clinical trials and ISTs, the clinical trials of AVB-500 having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in the Company's clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that AVB-500 may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that the Company may encounter difficulties in manufacturing AVB-500; if AVB-500 is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing the Company's intellectual property rights; the Company's reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, recent Current Reports on Form 8-K and subsequent filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 


 


 

 

Aravive, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

 

 

Three Months Ended

 

 

March 31,

 

 

2021

 

 

2020

 

Revenue

 

 

 

 

 

 

 

Collaboration revenue

$

256

 

 

$

 

Total revenue

 

256

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

5,884

 

 

 

3,491

 

General and administrative

 

2,380

 

 

 

3,951

 

Loss on impairment of long-lived assets

 

 

 

 

2,870

 

Total operating expenses

 

8,264

 

 

 

10,312

 

Loss from operations

 

(8,008

)

 

 

(10,312

)

Interest income

 

9

 

 

 

217

 

Other income (expense), net

 

(5

)

 

 

(701

)

Net loss

$

(8,004

)

 

$

(10,796

)

Net loss per share- basic and diluted

$

(0.44

)

 

$

(0.72

)

Weighted-average common shares used to compute

     basic and diluted net loss per share

 

18,067

 

 

 

15,013

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

Aravive, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

 

 

 

March 31,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(unaudited)

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

78,682

 

 

$

60,541

 

Restricted cash

 

2,430

 

 

 

2,430

 

Other assets

 

3,385

 

 

 

1,781

 

Operating lease right-of-use assets

 

2,770

 

 

 

2,958

 

Total assets

$

87,267

 

 

$

67,710

 

Liabilities and stockholders' equity:

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

$

4,252

 

 

$

4,823

 

Deferred revenue

 

6,059

 

 

 

6,315

 

Operating lease obligation

 

8,240

 

 

 

8,517

 

Total liabilities

 

18,551

 

 

 

19,655

 

Total stockholders' equity

 

68,716

 

 

 

48,055

 

Total liabilities and stockholders’ equity

$

87,267

 

 

$

67,710

 

 

 

 

Contact:

Joseph Schepers

VP, Investor Relations, Aravive, Inc.

jschepers@aravive.com

(770) 558-5517

 

Slide 1

Corporate Presentation May 2021 Halting Disease Progression in its Tracks ARAV (NASDAQ) © 2021 Aravive, Inc. Exhibit 99.2

Slide 2

Forward-Looking Statements Forward Looking Statements © 2021 Aravive, Inc. 2 This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and they often include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements included in this presentation include statements regarding Aravive’s planned clinical activities and the timing of such activities, including the design, patient enrollment and availability of data from clinical studies, the potential pipeline, future indications and cash position, the anticipated safety, benefits, activity and manufacturability of Aravive’s product candidates and the ability to obtain regulatory approval, including the Phase 3 study supporting full approval in PROC. Forward-looking statements are based on Aravive’s current beliefs and assumptions, are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: The trial supporting the submission of a biologics license application to the FDA, Aravive’s ability to conduct an interim analysis early next year, as planned, Aravive’s ability to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy as planned, Aravive’s ability to conduct the trial in the U.S. and Europe as planned, the impact of COVID-19 on Aravive's clinical strategy, clinical trials, supply chain and fundraising, Aravive's ability to expand development into additional oncology indications, Aravive's dependence upon AVB-500, AVB-500's ability to have favorable results in clinical trials and ISTs, the clinical trials of AVB-500 having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in Aravive's clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that AVB-500 may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that Aravive may encounter difficulties in manufacturing AVB-500; if AVB-500 is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing Aravive's intellectual property rights; Aravive's reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Aravive’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. Except as required by law, Aravive undertakes no obligation to revise or update any forward-looking statement or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Slide 3

© 2021 Aravive, Inc. 3 AVB-500 development program focused on difficult-to-treat cancers with high unmet medical needs Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Survival Proprietary, differentiated first-in-class therapeutic targeting and inhibiting GAS6/AXL signaling; GAS6/AXL is associated with tumor growth, metastasis, drug resistance, and poor survival rates Ongoing Phase 3 trial of AVB-500 to treat patients with platinum resistant ovarian cancer AVB-500 has potential in multiple indications and multiple therapeutic combinations Ongoing Phase 1b/2 trial of AVB-500 to treat patients with clear cell renal cell carcinoma Plan to initiate Phase 1b/2 trial of AVB-500 as first-line therapy for pancreatic cancer in 2H 2021

Slide 4

Experienced Management and Board of Directors Board of Directors Senior Management CEO Gail McIntyre, Ph.D., DABT CMO Reshma Rangwala, M.D., Ph.D. Chairman of the Board Fred Eshelman, Pharm D. Director Amato Giaccia, Ph.D. Director Michael Rogers Director Eric Zhang CFO Vinay Shah SVP of Data Sciences Randy Anderson, Ph.D. VP, Translational Medicine Elisabeth Gardiner, Ph.D. Director Gail McIntyre, Ph.D., DABT VP, Regulatory Jody Gould, Ph.D. VP, Clinical Operations Amy Franke, MBE © 2021 Aravive, Inc. 4

Slide 5

AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway and Blocking the Signaling AVB-500 © 2021 Aravive, Inc. 5

Slide 6

GAS6/AXL Signaling Pathway: Key Driver of Cancer Growth GAS6 and AXL are overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival GAS6 is growth factor that regulates several biologic processes in cells through interaction with its receptors, including AXL, Tyro3, and Mer GAS6 is the sole activating ligand of AXL GAS6/AXL signaling is key driver of cell migration/invasion, and associated with poor prognosis in cancer/fibrosis Pathway associated with acquired resistance to chemo, platinum-containing therapy, and targeted agents Inhibition of GAS6 & AXL has no toxicity to normal tissue Drives Resistance to Chemotherapy, Radiotherapy, Targeted Therapy, etc. Causes Immune Suppression Drives resistance to apoptosis/autophagy Leads to EMT and Metastasis Enhances cancer proliferation EMT = epithelial to mesenchymal transition © 2021 Aravive, Inc. 6

Slide 7

© 2021 Aravive, Inc. 7 GAS6 & AXL Expression Associated with Poor Survival in Many Cancers “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” Wu G, et al. Molecular insights of Gas6/TAM in cancer development and therapy; Cell Death and Disease (2017) 8, e2700. AXL expressed in >70% of ovarian, pancreatic, breast, kidney, and uterine cancers* *The Cancer Genome Atlas (TCGA); Axelrod and Pienta (AXL Review): Oncotarget. 2014 Oct; 5(19): 8818–8852; Miao et al (AXL Review): 2017. Drug Target Review Article 22309.

Slide 8

As an engineered decoy receptor with 200-fold higher affinity for GAS6 versus natural GAS6/AXL interaction, AVB-500 provides potent & selective inhibition of this signaling pathway. Other approaches targeting GAS6/AXL signaling have drawbacks: Tyrosine Kinase Inhibitors lack selectivity, leading to off-target toxicity, and tumor cells often acquire resistance Monoclonal antibodies do not have a high enough affinity to compete with and disrupt the high-affinity of natural GAS6/AXL interaction (Kd~30 pM) AVB-500: Addresses Limitations of Other Therapies © 2021 Aravive, Inc. 8

Slide 9

Forward-Looking Statements Clinical Pipeline Potential Opportunities for Expansion in Additional Indications and Drug Combinations Indication Preclinical Phase 1 Phase 3 Phase 2 © 2021 Aravive, Inc. 9 Anti-CTGF AVB-500 AVB-500 Investigator Sponsored Trials

Slide 10

Forward-Looking Statements Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC); Patients Have Advanced Disease and High Mortality 5th LEADING CAUSE OF DEATH among women in the U.S. ~70% OF PATIENTS are diagnosed with advanced disease 50% 5-YEAR RELATIVE SURVIVAL (9-12 months PROC) LESS THAN Ovarian Cancer © 2021 Aravive, Inc. 10 NEW CASES and ~13,800 deaths expected in the U.S. in 2021 ~21,400 NEW CASES and ~207,300 deaths worldwide in 2020 ~314,000 Sources: American Cancer Society (cancer.org); World Health Organization (who.int)

Slide 11

AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data AVB-500 q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 of 28-day cycle; Paclitaxel (PAC) 80 mg/m2 day 1, day 8, day 15 of 28-day cycle; Maintenance dosing on AVB-500 monotherapy PROC = platinum-resistant ovarian cancer iDMC= Independent Data Monitoring Committee NHV= Normal Healthy Volunteer RP2D= Recommend P2 Dose iDMC Review iDMC Review 84 subjects, including 31 healthy volunteers in Phase 1a trial and 53 patients with PROC in Phase 1b trial (40 in 10 mg/kg cohort, 6 in 15 mg/kg cohort, and 7 in 20 mg/kg cohort); NHV study identified 10mg/kg q2wks as pharmacologically active dose PROC patients administered 10mg/kg who achieved minimal efficacious concentration (MEC) >13.8 mg/L demonstrated a greater likelihood of response and prolonged PFS AVB-500 generally well-tolerated with no dose- limiting toxicities or unexpected safety signals, and no AVB-500 reportable serious adverse events 15 mg/kg chosen as RP2D for AVB-500 moving forward © 2021 Aravive, Inc. 11

Slide 12

Time on Treatment and Depth of Response for AVB-500 + Paclitaxel Patients (10 and 15mg/kg groups) © 2021 Aravive, Inc. 12

Slide 13

AVB-500 / Paclitaxel Combination Clinical Activity in Subgroups Note: AVB-500 + PAC and >MEC in bev naïve patients (n=7): mPFS 9.1 months and ORR of 71% Note: AVB-500 + PAC and <MEC: mPFS 2.8 months * Study ongoing so data can change; ** MEC = minimal efficacious concentration (13.8mg/L) For reference, subgroup analysis of the control arms in the AURELIA (NCT00976911) bevacizumab study1 showed ORR of 30.2% with PAC alone & mPFS of 3.9 months (N=55) ^1 patient at 10mg/kg and 1 patient at 15mg/kg had CR; 1 patient at 15mg/kg with CR continues to show CR at C13D1 while on AVB-500 alone, 6 months after discontinuing paclitaxel mDoR = median duration of response, mOS = median overall survival, mPFS = median progression free survival 1 Journal of Clinical Oncology, Vol 33, No 32 (November 10), 2015: pp 3836-383 © 2021 Aravive, Inc. 13

Slide 14

sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo Serum levels of sAXL/GAS6 ratio (potential biomarker) correlated with response to AVB-500 + Chemo Building dataset to understand prognostic ability of biomarker May identify tumors that are dependent on the GAS6/AXL pathway Investigating in P3 PROC, ccRCC and earlier lines of OC treatment CBR = clinical benefit rate (ORR + SD); mDoR = median duration of response; mOS = median overall survival; mPFS = median progression free survival © 2021 Aravive, Inc. 14

Slide 15

Promising Responses in Patients > MEC with Poor Prognostic Indicators CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PLATINUM FREE INTERVAL** (N=21) CLINICAL RESPONSE OF CHEMOTHERAPY IN 3rd LINE AND 4th LINE*** (N=99) *All doses and both chemo cohorts; **Historical data from Cancer Chemotherapy and Pharmacology (2019) 84:33-39 37; included PLD; GEM; CPT-11 (irinotecan); topotecan; and paclitaxel; no CRs in historical data (1 PR in historical data); ***European Journal of Obstetrics & Gynecology and Reproductive Biology 166 (2013) 94–98; 3L included (in order of use) taxol, carboplatin, topotecan, etoposide, Gemzar, doxil, tamoxifen, Adriamycin, carbo+taxol, and "other“; 4L was predominantly taxol. © 2021 Aravive, Inc. 15

Slide 16

Dose Selected for AVB-500 Phase 3 Trial in PROC is 15mg/kg 5/5 patients at 15mg/kg demonstrated clinical benefit: Consistent with hypothesis that trough levels are associated with clinical activity, all 5 evaluable patients in 15 mg/kg cohort achieved MEC by their first CT scan, following four doses of AVB-500. Updated modeling using all patient data suggest that at 15mg/kg, pharmacokinetics of AVB-500 starts to plateau and 20mg/kg is not predicted to improve mPFS. Post-hoc IHC analysis of tumor expression showed that four 20mg/kg patients whose best response was PD did not express GAS6 (N=3) and/or had low amounts of AXL (N=2) of their tumors. (Note these 20mg/kg patients are rare subtypes of PROC and will not be eligible for the planned Phase 3 trial.) 20mg/kg every 2 weeks projected to have unnecessarily high trough levels in a large percentage of subjects 15 mg/kg chosen as RP2D for AVB-500 © 2021 Aravive, Inc. 16

Slide 17

Strong Safety Profile of AVB-500 Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the concomitant treatment (PAC or PLD) and the disease under study (ovarian cancer).” AVB-500 well-tolerated: fatigue and infusion reactions appeared to be related to treatment No serious events that required expedited reporting per Sponsor No dose-limiting toxicities © 2021 Aravive, Inc. 17 53 PROC Patients Dosed: 10 mg/kg (40); 15 mg/kg (6); and 20 mg/kg (7)

Slide 18

Competitive Advantages of AVB-500 in PROC: Favorable Safety Profile and Compelling Anti-Tumor Activity Favorable Safety Profile to Date NO DLTs like chemotherapies and ADCs NO dose reductions or discontinuations to manage toxicities NO toxicities that have been seen with ADCs: neutropenia, ocular toxicities, peripheral neuropathy, and/or liver enzyme elevation Administered with therapies that physicians can manage Infusion reactions and fatigue appeared to be related to treatment Compelling anti-tumor activity Saw ORR of 50% with 2 CRs, mPFS of 7.5 months, and mOS of 19 months in 10 & 15mg/kg AVB-500/PAC patients when trough levels exceeded MEC Promising clinical activity improved in bevacizumab naïve patients ORR of 37% in 10 and 15mg/kg AVB-500/PAC patients, regardless of trough levels © 2021 Aravive, Inc. 18

Slide 19

Potentially More Favorable Benefit/Risk Profile vs Competitors For illustrative purposes only, Data not generated from comparative study. Variation in study design including patient eligibility, response criteria, and assessment can affect outcomes and limit comparisons across studies. **Sources: Mersana Therapeutics: Updated Interim Expansion Data From XMT-1536 Phase 1 Study (January 5, 2021); Immunogen ESMO 2019 FORWARD I Results © 2021 Aravive, Inc. 19

Slide 20

Forward-Looking Statements AVB-500 Phase 3 Adaptive Registration Trial Design in PROC © 2021 Aravive, Inc. 20 FDA Feedback: Study could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time; AVB-500 granted Fast Track Designation by FDA in PROC in 2018 Population: Patients (n=300-400) with PROC, ability to adapt and enrich based on interim analysis 300 patients (no enrichment) 400 patients (if enriched for bevacizumab naïve1 patients) Enrollment Criteria: Patients with high-grade serous ovarian cancer only; stratified by prior bevacizumab use, prior lines, and platinum-free interval Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Compare Efficacy and Tolerability of AVB-500 + PAC versus PAC (ClinicalTrials.gov NCT04729608 ) Primary Endpoint: Progression-Free Survival Secondary Endpoint: Overall Survival Exploratory Endpoints: ORR (RECIST 1.1), DOR, QoL, CBR, PK/PD, sAXL/GAS6 ratio Dosing: AVB-500 every 2 weeks plus paclitaxel for 3 weeks, followed by 1 week rest versus paclitaxel alone every week for 3 weeks, followed by 1 week rest Timeline: First patient dosed in April 2021; Interim analysis expected in Q1 2022 1 naïve defined as patients who are medically ineligible to receive bevacizumab or who chose not to receive bevacizumab

Slide 21

Forward-Looking Statements Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma; Patients Have Very Poor Survival Rates Renal Cell Carcinoma 15% ~76,100 RESISTANCE To CHEMO LESS THAN 5-YEAR RELATIVE SURVIVAL for metastatic renal cancer NEW CASES and ~13,800 deaths expected in the U.S. in 2021 IS COMMON © 2021 Aravive, Inc. 21 ~431,300 NEW CASES and ~179,400 deaths worldwide in 2020 Sources: American Cancer Society (cancer.org); World Health Organization (who.int)

Slide 22

Forward-Looking Statements Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC GAS6/AXL in clear cell Renal Cell Carcinoma (ccRCC)1 AXL plays significant role in ccRCC invasion & metastasis AXL highly expressed in aggressive ccRCC tumors and associated with poor outcome GAS6/AXL signaling pathway is established therapeutic target to prevent/treat metastatic ccRCC Strong in vivo activity in preclinical models1,2 Single agent AVB-500 activity in metastatic disease Data support combination of AVB-500 & antiangiogenic agents for treatment of advanced kidney cancer GAS6/AXL levels predict prognosis and survival in humans1,2 1. Rankin et al, PNAS | September 16, 2014 | vol. 111 | no. 37 | 13375; 2. Xiao et al, Cancer Research October 4, 2019 © 2021 Aravive, Inc. 22

Slide 23

Forward-Looking Statements Single Agent Activity in Highly Metastatic Renal Model (SN12L1) 5mg/kg AXL decoy administered twice/wk 10 mg/kg administered QOD Rankin et al, PNAS, September 16, 2014, vol. 111, no. 37, 13373–13378 Note: S6-1 and AVB-S6 are related AXL decoy proteins; both in S6 family Therapeutic inactivation of AXL significantly reduces the metastatic potential of SN12L1 cells to the lung P ≤ 0.05 Lung Tumor Burden PBS sAXL © 2021 Aravive, Inc. 23

Slide 24

Forward-Looking Statements Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX AVB-500/Pazopanib Combination Significantly Reduced Growth Rate in TKI-Resistant Renal Patient-Derived Xenograft Models Xiao et al, Cancer Res 2019;79:5758–68; *note AVB-S6 is AVB-500 © 2021 Aravive, Inc. 24

Slide 25

Forward-Looking Statements AVB-500 + Cabozantinib Phase 1b/2 Trial Design in ccRCC Phase 1b Trial of AVB-500 in Combination with Cabozantinib Up to 18 patients; ability to increase/decrease dose based on tolerability, PK/PD Histologically confirmed metastatic ccRCC and patient has progressed on/after one front-line treatment regimen First patient dosed in March 2021; Completion of enrollment expected in Q3 2021 Phase 2 Controlled, Randomized Trial Primary Endpoint: Progression-Free Survival Secondary Endpoints: ORR, mDoR, CBR, and mOS Initiation of Phase 2 trial expected in Q4 2021 © 2021 Aravive, Inc. 25 AVB-500 + Cabo (N = 9-18) AVB-500 Dose Levels: DL -1: 10 mg/kg 2QW DL 1: 15 mg/kg Q2W DL 2: 20 mg/kg Q2W DL 3: 25 mg/kg Q2W AVB-500+Cabo (N=30) Cabo Alone (N=15) Safety to determine AVB-500 RP2D Cabo dosing will remain as indicated on the package insert

Slide 26

Planned Third Indication: AVB-500 in Pancreatic Cancer; High Unmet Medical Need to Improve Patient Survival © 2021 Aravive, Inc. 26 Sources: Pancreatic Cancer Overview | American Association for Cancer Research (aacr.org); World Health Organization (who.int) Pancreatic Cancer ~11% 5-YEAR RELATIVE SURVIVAL Patients with pancreatic cancer have a high mortality rate ~60,400 NEW CASES and ~48,200 deaths expected in the U.S. in 2021 ~495,800 NEW CASES and ~466,000 deaths worldwide in 2020 Difficult to diagnose and treat Usually not found until progressed to an advanced stage Pancreas is critical to digestion and producing insulin and glycogen to control blood sugar levels

Slide 27

© 2021 Aravive, Inc. 27 Preclinical data demonstrated increased survival in combination with gemcitabine, decreased fibrosis, and decreased tumor weight in orthotopic models AVB-500 in combination with paclitaxel demonstrated compelling clinical activity in PROC Studies have reported AXL expression correlates with worse outcome in clinical samples from pancreatic cancer patients1,2 70% and 76% of patients had tumor tissues with high AXL levels, which was associated with worse prognosis, distant metastasis, and poor overall survival and recurrence-free survival AXL silencing by shRNA decreased cell invasion, Akt activation, and increased radiation-induced PARP cleavage and apoptosis1; pancreatic ductal adenocarcinoma cell lines with shRNA knockdown of AXL resulted in reduced tumor growth and metastasis in vivo Strong Biological Rationale for Investigating AVB-500 in Pancreatic Cancer as First-Line Therapy in Combination with Gemcitabine + nab-Paclitaxel (Abraxane®) 1 Song X, Wang H, Logsdon CD, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011 2 15;117(4): 734–43. 2 Leconet W, Larbouret C, Chardes T, et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene 2014 11 20;33(47):5405–14. 3 Kirane A, Ludwig KF, Sorrelle N, et al. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Res 2015 9 15;75(18):3699– 705.

Slide 28

High Affinity AXL Decoy Proteins Decrease Fibrosis, Prolong Survival, and Decrease Tumor Weight Alone or in Combination with Gemcitabine in Pancreatic Models – Compelling Pre-Clinical Data LM-P Tumor (Kras, p53 mutant) Implanted in Tail of Pancreas Survival increased 3-fold Fibrosis dramatically decreased with high affinity AXL decoy protein alone MS Kariolis, et al.,. J. Clin. Invest, 2017 S6-1 A72V and S6-1 are predecessor proteins to AVB-500 with same biological activity Significant reduction in tumor weight with high affinity AXL decoy protein as compared to vehicle alone © 2021 Aravive, Inc. 28 PDA1-1 injected IP to establish diffuse metastatic disease

Slide 29

Forward-Looking Statements AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Cancer © 2021 Aravive, Inc. 29 Population: Patients (n=20) with advanced or metastatic pancreatic cancer eligible to receive gemcitabine + nab-paclitaxel as first-line treatment Assess safety, tolerability and clinical activity of AVB-500 in combination with gemcitabine + nab-paclitaxel (Abraxane®) Timeline: Expect to initiate Phase 1b portion of clinical trial in second half 2021 AVB-500 (15mg/kg) + Gemcitabine + nab-paclitaxel Safety, tolerability and clinical activity Phase 1b Planned Phase 1b Trial of AVB-500 in Combination with Gemcitabine + nab-Paclitaxel

Slide 30

© 2021 Aravive, Inc. 30 AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Cancer Population: Patients (n=60) with advanced or metastatic pancreatic cancer eligible to receive gemcitabine + nab-paclitaxel as first-line treatment (same population as Phase 1b) Randomized 1:1, active:control Design: Evaluate AVB-500 in combination with gemcitabine + nab-paclitaxel (Abraxane®) vs. gemcitabine + nab-paclitaxel alone Primary Endpoint: Progression-Free Survival Secondary Endpoints: OS, safety, ORR, DOR Exploratory Endpoints: PK/PD AVB-500+ Gemcitabine + nab-paclitaxel (N=30) Gemcitabine + nab-paclitaxel (N=30) Phase 2 Gemcitabine + nab-paclitaxel dosing per package insert Planned Controlled, Randomized Phase 2 Trial

Slide 31

© 2021 Aravive, Inc. 31 Preclinical data suggests that AVB-500 has potential in multiple combinations and indications: Reduction of metastases to lung (breast and renal models) Reduction of metastases to peritoneum (ovarian and pancreatic models) Decreased fibrosis in pancreatic model Decreased metastasis in pancreatic model Survival tripled in pancreatic model relative to control Reduction in number and weight of metastases in combination with doxorubicin, paclitaxel, bevacizumab and PARP inhibitors Reversal of CPI- and radiation-resistance in TNBC model Forward-Looking Statements Development Strategy: Conduct Additional Trials to Expand Pipeline Combination trials with agents currently embedded as standard of care Earlier lines of therapy Multiple tumor types Preclinical data on AVB-500 includes:

Slide 32

AVB-500: Large Market Opportunities in PROC, ccRCC, Pancreatic Cancer & Other Indications 2L-4L platinum-resistant ovarian cancer (PROC), high grade serous patients 2L advanced/metastatic clear cell renal cell carcinoma (ccRCC) patients Adenocarcinoma – Metastatic 1L, eligible to receive gemcitabine + nab-paclitaxel as 1L treatment HER2 negative 2L+ patients (includes HR positive and TNBC) Adenocarcinoma, Squamous and Large Cell non small cell lung cancer (NSCLC) – Metastatic 2L and 3L, patients who have received platinum chemo and checkpoint inhibitor before, EGFR/ALK wt 1L advanced/metastatic, Cisplatin ineligible Source: Decision Resource Group. Covers US, EU5 (France, Germany, Italy, Spain, UK) and Japan Source: Decision Resource Group, diagnosed drug-treatable patients forecast. Aravive estimates. Total US EU5 ~181K ~208K © 2021 Aravive, Inc. 32

Slide 33

Forward-Looking Statements Strategic Collaboration with WuXi Biologics for High-Affinity Bispecific Antibodies Objective is to identify/develop novel, high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), targeting cancer/fibrosis using WuXiBody™ platform CTGF over-expression is hallmark of fibrosis in multiple tissues and is widely thought to be required to mediate profibrotic effects of TGFβ Overexpression associated with poor prognosis in many cancers, including aggressive/invasive breast cancer, osteolytic breast cancer, pancreatic cancer, and glioblastoma Biomarker potential for CTGF as levels are increased in certain cancers Domain-focused strategy expected to generate a best-in-class clinical therapeutic targeting desmoplasia and tumor growth in 2023 Initial target anticipated to be pancreatic ductal adenocarcinoma (PDAC) CTGF may play key role in PDAC progression & blocking it could prevent/reverse PDAC desmoplasia Therapeutic could work as part of life cycle management with AVB-500 in certain cancers © 2021 Aravive, Inc. 33

Slide 34

Forward-Looking Statements 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China for Oncology Indications Exclusive collaboration and license agreement for development & commercialization of AVB-500 across all oncology indications in mainland China, Hong Kong, Macau, and Taiwan (Greater China) Aravive received upfront payment of $12M and is eligible to receive additional $207M in development and commercial milestone payments Achieved first clinical milestone and expected to receive $6.0 million development milestone payment Aravive will receive tiered-royalties ranging from low double-digit to mid-teens as a % of annual net sales 3D Medicines will be responsible for all costs associated with development and commercialization activities for AVB-500 in Greater China “We believe that AVB-500, used in combination with existing standard of care therapeutics or Envafolimab, an innovative subcutaneous PD-L1 antibody to be launched in China soon, could alter the treatment paradigm across various tumor types. We are committed to working closely with Aravive to further advance the development of AVB-500 and bring this important potential therapy to patients living with cancer in China,” John Gong, M.D., Ph.D., Chairman/CEO of 3D Medicines* *Source: Aravive & 3D Medicines press release November 10, 2020 © 2021 Aravive, Inc. 34

Slide 35

Forward-Looking Statements Financial Summary * Data as of 3/31/2021 © 2021 Aravive, Inc. 35 $78.7 million cash and cash equivalents 20.3 million shares outstanding No debt Cash runway expected to fund current operating plans into 2H 2022 Achieved first clinical milestone with 3D Medicines and expected to receive $6.0 million development milestone payment

Slide 36

Aravive Top Shareholders Insiders, Institutional Shareholders Make Up approx. 70% of Our Outstanding Shares © 2021 Aravive, Inc. 36 * As per SEC filings – 13D, 13F, 13G, Forms 3 and Form 4, Proxy ** As of 12/31/2020, adjusted for Eshelman Ventures investment in Feb-21

Slide 37

Forward-Looking Statements Upcoming Key Milestones Advancing Our Clinical Development Program © 2021 Aravive, Inc. 37 Q3 2021 Q4 2021 Q1 2022 2021 and Beyond Completion of enrollment in Phase 1b ccRCC trial Initiation of Phase 2 ccRCC trial Planned initiation of Phase 1b Pancreatic Cancer trial Interim analysis for Phase 3 PROC trial Data from IST-sponsored trials & anti-CTGF discovery program Pipeline expansion in oncology Execution of global business development opportunities

Slide 38

© 2021 Aravive, Inc. 38 Focused on difficult-to-treat cancers: AVB-500 lead indication in advanced stage ovarian cancer; registrational Phase 3 clinical trial ongoing Advancing AVB-500 Clinical Trial Program & Pursuing Additional Pipeline Expansion Opportunities AVB-500 targets and inhibits GAS6/AXL signaling which is associated with tumor growth, metastasis, drug resistance, and poor patient survival AVB-500 is a differentiated innovative approach that addresses the inadequacies and limitations of other therapies Potential for expansion in multiple indications and combinations with AVB-500 Strong Management Team and Board of Directors Upcoming key milestones to advance our clinical development program

Slide 39

Thank you! Halting Disease Progression in its Tracks © 2021 Aravive, Inc.